AB0682

CIRCULATING FIBROCYTES IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS: CORRELATION WITH DERMAL THICKNESS

Barbara Ruaro¹, Stefano Soldano¹, Vanessa Smith^{2,3,4}, Sabrina Paolino¹, Carmen Pizzorni¹, Paola Contini⁵, Paola Montagna¹, Samuele Tardito¹, Maurizio Cutolo¹. ¹Research Laboratory and Academic Division of Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy; ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; ³Department of Internal Medicine, Ghent University, Ghent, Belgium; ⁴Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Italy; ⁵Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy

Background: Systemic sclerosis (SSc) is characterized by early skin impairment (1,2) and the modified Rodnan skin score (mRSS) is the validated method to assess the severity of this impairment. Whilst skin high frequency ultrasound (US) is a relatively new technique to measure dermal thickness (DT) (2-4).

Recent findings have reported the important contribution circulating fibrocytes make in the early stage of dermal repair and fibrosis. Indeed, as fibrocytes may be an important source of activated fibroblasts/myofibroblasts, it is reasonable to presume that they could be responsible for the increase in these cells observed in the tissue of SSc patients (5-7).

Objectives: The aim of this study was to identify any correlation between the modified Rodnan skin score (mRSS), dermal thickness (DT), measured by skin high frequency ultrasound (US) and the percentage of circulating fibrocytes in patients with limited cutaneous systemic sclerosis (lcSSc).

Methods: After obtaining approval and written informed consent and the Ethics Committee approval 8 lcSSc patients (7 females, 1 male) and 5 (4 females, 1 male) age-matched healthy volunteers (CNT) were enrolled. The lcSSc patients fulfilled the 2013 ACR/EULAR criteria for SSc (8). DT was evaluated by both mRSS and US (18 and 22 MHz probes), in all SSc patients and CNT, in the standard 17 skin areas evaluated by mRSS. The percentage of circulating fibrocytes was obtained by isolating them from the peripheral blood mononuclear cells (PBMCs) in all lcSSc patients and CNTs. Non-parametric tests were used for the statistical analysis.

Results: The percentage of circulating fibrocytes was positively correlated with DT-US, evaluated by the 22 MHz and the 18 MHz probes ($p=0.04$ and $p=0.03$, respectively) and mRSS ($p=0.04$) in lcSSc patients. Conversely, there was no correlation between these parameters in the CNT group ($p>0.05$).

Conclusion: The study demonstrates a significant relationship between DT, evaluated by both mRSS and US and the percentage of circulating fibrocytes in lcSSc patients. This observation may well support the hypothesis that circulating fibrocytes make a crucial contribution to skin fibrosis progression.

REFERENCES

- Cutolo M, et al. Best Pract Res Clin Rheumatol. 2016;30:670-87.
- Krieg T, et al. Rheumatology 2009;48:iii14-8.
- Clements PJ, et al. J Rheumatol 1995;22:1281-5.
- Ruaro B, et al. Arthritis Rheumatol 2015; 67 (suppl 10).
- Cutolo M, et al. Arthritis Res Ther. 2018;20:157.
- Brunasso AM, et al. F1000Res. 2016 Apr 22;5. doi: 10.12688/f1000research.7986.1.
- Reilkoff R, et al. Nat Rev Immunol. 2011;11:427-35.
- van den Hoogen F, et al. Ann Rheum Dis. 2013;72:1745-55.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.1746

AB0683

ROLE OF ELASTIN AND ELASTASE ANTIBODIES IN DEVELOPMENT OF PNEUMOSCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA

Olga Rusanova, I Gontar, Olga Emelyanova, Krasilnikov Andrey. Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A. B. Zborovskyy», Volgograd, Russian Federation

Background: Disturbed elastin metabolism, emerging pathological soluble isoforms followed by triggering of autoimmunity show that the biopolymer under study is associated with the pathogenesis of polyorganic lesions in systemic sclerosis. Elastin catabolism is promoted by elastase, an enzyme with a broad-range substrate specificity. It is the balance of a dynamic elastin–elastase system that determines physiological functioning of organs and tissues containing elastic fibres: the skin, ligaments, lungs,

and vascular walls. Antibodies to elastin and elastase are unique predictors of development of pulmonary conditions in systemic scleroderma, which is now considered to be one of risk factors for pulmonary lesion.

Objectives: Developing highly sensitive markers of pulmonary remodeling at early stages of systemic scleroderma with participation of humoral immunity to the elastin–elastase system in the development of pulmonary lesion in systemic scleroderma requires further detailed study.

Methods: Patients for the study were selected from the department of rheumatology at the Emergency Care Municipal Hospital 25 in the city of Volgograd. The main group incorporated 42 persons with the diagnosis of systemic scleroderma verified by ACR/EULAR diagnostic criteria of 2013, without any exclusion criteria. There were 11 men and 31 women aged 22–72 among the systemic scleroderma patients. The mean age of patients was 44.1 ± 15.4 . The control group incorporated 30 healthy donors at the Volgograd Regional Blood Transfusion Station. Antibodies to elastin and elastase were determined in the blood serum by indirect enzyme immunoassay utilizing insoluble forms with enhanced antigen content according to the original technique by Gontar et al (1990).

Results: Compared with the control group, patients with systemic scleroderma showed a considerably higher rate of antibodies to elastase (52%) and elastin (38%). The upper normal level of antibodies to elastin was in the range of 0.131 absorbance units, of antibodies to elastase – 0.131 absorbance units. The mean value of elastin antibodies in the blood of systemic scleroderma patients was 0.125 ± 0.068 absorbance units. The value of elastase antibodies was 0.143 ± 0.071 absorbance units. The elevated level of elastin and elastase antibodies in the patients was associated with pulmonary lesion (basal pulmonary fibrosis – 20 (47.6%), pulmonary hypertension – 11 (26.2%), and adhesive pleurisy – 7 (16.7%). In one half of cases the pulmonary lesion was asymptomatic, detected by accessory investigations like X-ray of chest organs, respiratory function study, EchoCG which were administered to assess the extent of abdominal organ inflammation and in differential diagnosis with cardiac insufficiency. The level of elastin antibodies in systemic scleroderma patients with pulmonary lesion was 0.149 ± 0.074 absorbance units, and of elastase antibodies – 0.146 ± 0.043 absorbance units, which was considerably higher than mean values in the control group.

Conclusion: By determining antibodies to elastin and elastase by the proposed technique of enzyme immunoassay at early stages of systemic scleroderma one can predict lesions of pulmonary parenchyma presenting with various clinical signs, and exacerbation of fibrosis processes.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.1535

AB0684

DO WE DIAGNOSE ALL THE ANTISYNTHEASE SYNDROME?

Meritxell Sallés Lizarzaburu¹, Sonia Mínguez¹, Saul Mario Gelman¹, Roser Tuneu¹, Mercè López de Recalde¹, Basilio Rodríguez¹, Jaume Trapé², Damià Perich³, Anna Muñoz³, Sandra Ros³, Oscar Bernadich³, Josep Gonzalez⁴. ¹Althaia Xarxa Assitencial Universitària de Manresa, Rheumatology, Manresa, Spain; ²Althaia Xarxa Assitencial Universitària de Manresa, Clinical Laboratory, Manresa, Spain; ³Althaia Xarxa Assitencial Universitària de Manresa, Pneumology, Manresa, Spain; ⁴Althaia Xarxa Assitencial Universitària de Manresa, Internal Medicine, Manresa, Spain

Background: Antisynthetase syndrome (AS) is an autoimmune disease characterized by the presence of anti-aminoacyl tRNA-synthetase antibodies (anti-ARS) and clinical manifestations that may include interstitial lung disease (ILD), myositis, non erosive arthritis, Raynaud's phenomenon (RP), fever and mechanic's hands. Until the Connors diagnostic criteria appeared in 2010, these patients with anti-ARS antibody were classified as an idiopathic inflammatory myopathy, or if they did not present myositis, they remained undiagnosed.

Objectives: To identify patients with anti-ARS antibodies from our hospital since June 2015, when the immunology laboratory was inaugurated, and to verify if they fulfilled the AS criteria.

Methods: Retrospective observational study carried out in a regional hospital in Barcelona with a reference population of 260,000 inhabitants. All patients with any anti-ARS antibody (Jo1, PL7, PL12, EJ) positive were selected, determined by the Dot Blot Polymyositis/Scleroderma IgD D-Teck. We applied Connors diagnostic criteria and collected demographic, clinical and instrumental data, and types of antibodies.

Results: We identified 18 patients with anti-ARS antibody, 9 anti-Jo1 (53%), 4 anti-PL7, 3 anti-PL-12 and 1 anti-EJ. Of these, 13 had values of ANA > 1/80, 3 values of 1/80 and 1 negative. Other antibodies identified were anti-Ro52 in 4, anti-DNA in 4 and anti-Scl70 in 1. All patients except one met AS criteria. None of anti-DNA positive subjects met criteria for erythematosus systemic lupus or systemic sclerosis. The majority